

World Journal of *Gastroenterology*

World J Gastroenterol 2017 May 28; 23(20): 3569-3760



**EDITORIAL**

- 3569 Hepatitis C in injection drug users: It is time to treat
Grassi A, Ballardini G
- 3572 Cyclooxygenase 2 in liver dysfunction and carcinogenesis: Facts and perspectives
Martín-Sanz P, Casado M, Boscá L

REVIEW

- 3581 First quarter century of laparoscopic liver resection
Morise Z, Wakabayashi G
- 3589 Hepatitis A virus infection and hepatitis A vaccination in human immunodeficiency virus-positive patients: A review
Lin KY, Chen GJ, Lee YL, Huang YC, Cheng A, Sun HY, Chang SY, Liu CE, Hung CC
- 3607 Brain changes detected by functional magnetic resonance imaging and spectroscopy in patients with Crohn's disease
Lv K, Fan YH, Xu L, Xu MS
- 3615 Perspectives of traditional Chinese medicine in pancreas protection for acute pancreatitis
Li J, Zhang S, Zhou R, Zhang J, Li ZF

MINIREVIEWS

- 3624 Transition of pediatric to adult care in inflammatory bowel disease: Is it as easy as 1, 2, 3?
Afzali A, Wahbeh G
- 3632 Colorectal cancer population screening programs worldwide in 2016: An update
Navarro M, Nicolas A, Ferrandez A, Lanás A

ORIGINAL ARTICLE**Basic Study**

- 3643 Urinary metabolic insights into host-gut microbial interactions in healthy and IBD children
Martin FP, Su MM, Xie GX, Guiraud SP, Kussmann M, Godin JP, Jia W, Nydegger A
- 3655 M2-like Kupffer cells in fibrotic liver may protect against acute insult
Zheng QF, Bai L, Duan ZP, Han YP, Zheng SJ, Chen Y, Li JS

- 3664** Sonographic appearance of anal cushions of hemorrhoids

Aimaiti A, A Ba Bai Ke Re MMTJ, Ibrahim I, Chen H, Tuerdi M, Mayinuer

- 3675** Effect of NDC80 in human hepatocellular carcinoma

Ju LL, Chen L, Li JH, Wang YF, Lu RJ, Bian ZL, Shao JG

- 3684** Animal experimental studies using small intestine endoscope

Liu JH, Liu DY, Wang L, Han LP, Qi ZY, Ren HJ, Feng Y, Luan FM, Mi LT, Shan SM

Retrospective Cohort Study

- 3690** Radiological response and inflammation scores predict tumour recurrence in patients treated with transarterial chemoembolization before liver transplantation

Nicolini D, Agostini A, Montalti R, Mocchegiani F, Mincarelli C, Mandolesi A, Robertson NL, Candelari R, Giovagnoni A, Vivarelli M

Retrospective Study

- 3702** Surgical management of liver diseases invading the hepatocaval confluence based on IH classification: The surgical guideline in our center

Li W, Han J, Wu ZP, Wu H

Observational Study

- 3713** Study on the value of serum miR-106b for the early diagnosis of hepatocellular carcinoma

Shi BM, Lu W, Ji K, Wang YF, Xiao S, Wang XY

Prospective Study

- 3721** Clinical significance of expression of proliferating cell nuclear antigen and E-cadherin in gastric carcinoma

Hu L, Li HL, Li WF, Chen JM, Yang JT, Gu JJ, Xin L

META-ANALYSIS

- 3730** Different techniques for harvesting grafts for living donor liver transplantation: A systematic review and meta-analysis

Li H, Zhang JB, Chen XL, Fan L, Wang L, Li SH, Zheng QL, Wang XM, Yang Y, Chen GH, Wang GS

CASE REPORT

- 3744** Successful treatment of a pancreatic schwannoma by spleen-preserving distal pancreatectomy

Xu SY, Wu YS, Li JH, Sun K, Hu ZH, Zheng SS, Wang WL

- 3752** Preoperative detection and localization of small bowel hemangioma: Two case reports

Takase N, Fukui K, Tani T, Nishimura T, Tanaka T, Harada N, Ueno K, Takamatsu M, Nishizawa A, Okamura A, Kaneda K

LETTERS TO THE EDITOR

- 3758** Non-invasive stimulation techniques to relieve abdominal/pelvic pain: Is more always better?

Harvey MP, Watier A, Dufort Rouleau É, Léonard G

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Jia Liu, MD, Associate Professor, Department of Infectious Diseases, Institution of Infection and Immunology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei Province, China

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents[®]/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch[®]), Journal Citation Reports[®], Index Medicus, MEDLINE, PubMed, PubMed Central, Digital Object Identifier, and Directory of Open Access Journals. The 2015 edition of Journal Citation Reports[®] released by Thomson Reuters (ISI) cites the 2015 impact factor for *WJG* as 2.787 (5-year impact factor: 2.848), ranking *WJG* as 38 among 78 journals in gastroenterology and hepatology (quartile in category Q2).

FLYLEAF

I-IX Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Cai-Hong Wang*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Yuan Qi*
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF

Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS

All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE

Jin-Lei Wang, Director
Yuan Qi, Vice Director
Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER

Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE
May 28, 2017

COPYRIGHT

© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS

Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>

Basic Study

M2-like Kupffer cells in fibrotic liver may protect against acute insult

Qing-Fen Zheng, Li Bai, Zhong-Ping Duan, Yuan-Ping Han, Su-Jun Zheng, Yu Chen, Jian-Sheng Li

Qing-Fen Zheng, Jian-Sheng Li, Department of Gastroenterology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China

Li Bai, Zhong-Ping Duan, Su-Jun Zheng, Yu Chen, Artificial Liver Center, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Yuan-Ping Han, Center for Growth, Metabolism and Aging, Key Laboratory for Bio-Resource and Eco-Environment, College of Life Sciences, Sichuan University, Chengdu 610014, Sichuan Province, China

Yuan-Ping Han, National Key Laboratory of Biotherapy, Sichuan University, Chengdu 610014, Sichuan Province, China

Author contributions: Zheng QF, Bai L and Duan ZP contributed equally to this work; Zheng QF and Bai L performed the majority of experiments and wrote the paper; Duan ZP analyzed the data and revised the paper; Han YP, Zheng SJ and Chen Y participated equally in the treatment of animals; Li JS designed the research.

Supported by Special Fund of Clinical Medicine, Beijing Municipal Administration of Hospitals, No. XM201308; Ascent Plan of Beijing Municipal Administration of Hospitals, No. DFL20151601; YouAn Fund for Liver Diseases and AIDS, No. YNKT20160012; Startup Fund from Sichuan University, Beijing Municipal Science and Technology Commission, No. Z131107002213019 and No. Z151100004015066; and the Basic-Clinical Cooperation Project of Capital Medical University, No. 17JL47.

Institutional review board statement: This study was reviewed and approved by the Capital Medical University Institutional Review Board.

Institutional animal care and use committee statement: All procedures involving animals were reviewed and approved by the Institutional Animal Care and Use Committee of Capital Medical University (AEEI-2014-071).

Conflict-of-interest statement: The authors declare that they have no conflict of interest related to this study.

Data sharing statement: No additional data are available.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Correspondence to: Jian-Sheng Li, Professor, Department of Gastroenterology, First Affiliated Hospital of Zhengzhou University, No. 1, Jianshe East Road, Zhengzhou 450052, Henan Province, China. lijiansheng@medmail.com.cn
Telephone: +86-371-66862052

Received: January 10, 2017

Peer-review started: January 10, 2017

First decision: February 9, 2017

Revised: February 21, 2017

Accepted: March 30, 2017

Article in press: March 30, 2017

Published online: May 28, 2017

Abstract

AIM

To investigate the mechanism of hepatoprotection conferred by liver fibrosis through evaluating the activation phenotype of kupffer cells.

METHODS

Control and fibrotic mice were challenged with a lethal dose of D-GalN/lipopolysaccharide (LPS), and hepatic damage was assessed by histology, serum alanine transferase (ALT) levels, and hepatic expression of HMGB1, a potent pro-inflammatory mediator. The

localization of F4/80 (a surrogate marker of KCs), HMGB1, and type I collagen (Col-1) was determined by immunofluorescence staining. The phenotype of KCs was characterized by real-time PCR. KCs isolated from control or fibrotic mice were challenged with LPS or HMGB1 peptide, and HMGB1 translocation was analyzed.

RESULTS

Liver fibrosis protected mice against D-GalN/LPS challenge, as shown by improved hepatic histology and reduced elevation of ALT compared with the normal mice treated in the same way. This hepatoprotection was also accompanied by inhibition of HMGB1 expression in the liver. Co-localization of F4/80, HMGB1, and Col-1 was found in fibrotic livers, indicating the close relationship between KCs, HMGB1 and liver fibrosis. KCs isolated from fibrotic mice predominantly exhibited an M2-like phenotype. *In vitro* experiments showed that HMGB1 was localized in the nucleus of the majority of M2-like KCs and that the translocation of HMGB1 was inhibited following stimulation with LPS or HMGB1 peptide, while both LPS and HMGB1 peptide elicited translocation of intranuclear HMGB1 in KCs isolated from the control mice.

CONCLUSION

M2-like Kupffer cells in fibrotic liver may exert a protective effect against acute insult by inhibiting the translocation of HMGB1.

Key words: Liver fibrosis; Injury resistance; Kupffer cell activation; High-mobility group box 1; Translocation

© **The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: The hepatoprotective effect conferred by liver fibrosis against acute liver injury is an interesting phenomenon, which has not yet been fully characterized. In the present study, we dissected the underlying mechanism of acute injury in the setting of liver fibrosis through investigating the correlation between KC activation and HMGB1 translocation. Our study showed that liver fibrosis protects mice against D-GalN/LPS challenge, and M2-like KCs in the fibrotic liver may exert a protective effect by inhibiting the translocation of HMGB1, a potent pro-inflammatory mediator.

Zheng QF, Bai L, Duan ZP, Han YP, Zheng SJ, Chen Y, Li JS. M2-like Kupffer cells in fibrotic liver may protect against acute insult. *World J Gastroenterol* 2017; 23(20): 3655-3663 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i20/3655.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i20.3655>

INTRODUCTION

Liver fibrosis is the most clinically relevant consequence

of chronic liver diseases. It is characterized by the activation of hepatic stellate cells and the excessive accumulation of extracellular matrix^[1]. Advanced fibrosis results in cirrhosis, portal hypertension and liver failure, and often requires liver transplantation^[2-5]. On the other hand, liver fibrosis represents the wound healing response to liver injury due to a variety of etiologies^[6,7]. Recently, increasing attention has been focused on the homeostatic and beneficial effects originating from fibrotic liver. Convincing evidence has shown that fibrosis results in increased liver resistance to subsequent acute insults, thus protecting hepatocytes against various toxic stimuli^[8-10]. However, the mechanisms governing this hepatoprotection are largely unexplored.

Hepatic macrophages have central roles in maintaining homeostasis in the liver as well as in the pathogenesis of acute or chronic liver injury^[11]. Macrophages are pleiotropic cells that assume diverse functions. The microenvironmental milieu is a key determinant of macrophage function during tissue inflammation^[12]. Macrophages can undergo "classical" M1 activation when exposed to lipopolysaccharide (LPS), and interferon-gamma (IFN- γ) or "alternative" M2 activation when exposed to interleukin (IL)-4/IL-13^[13-15]. M1- and M2-like macrophages exhibit distinct signatures and fulfill different functions. Kupffer cells (KCs), the resident macrophages in the liver, play pivotal roles in the progression and resolution of liver fibrosis^[16]. Recently, KCs have been reported to exert a protective effect against tumor necrosis factor (TNF)- α -induced hepatocyte apoptosis^[9]. Nevertheless, whether and how KC activation is involved in injury resistance in the setting of liver fibrosis is poorly understood.

HMGB1 is a ubiquitous protein present in the nucleus of most mammalian cells. HMGB1 has diverse functions which depend on its cellular localization. In the intracellular compartment, HMGB1 participates in gene transcription, DNA replication, and DNA repair. To function as a damage-associated molecular pattern (DAMP), HMGB1 can translocate from nucleus to cytoplasm and is subsequently released into the extracellular milieu. This process is implemented by two principal means: active secretion by innate immune cells (*e.g.*, macrophages) after hyperacetylation or passive release from necrotic cells. Extracellular HMGB1 activates pro-inflammatory signaling pathways by ligation of pattern recognition receptors including the receptor for advanced glycation end products or Toll-like receptor 4, leading to severe damage in multiple liver diseases^[17-19]. As a biomarker of liver injury, HMGB1 is superior to serum alanine transferase (ALT) levels at identifying acetaminophen-induced acute liver injury and elevated HMGB1 in acute liver failure correlates well with poor outcome^[20,21].

In the present study, we investigated the roles of KCs, KC activation, and HMGB1 in the pathogenesis

of acute injury in the setting of liver fibrosis, and hypothesized that activated KCs in fibrotic liver protected against acute insult by inhibiting the translocation of HMGB1. We present herein evidence that liver fibrosis protects mice against D-GalN/LPS challenge and that M2-like KCs in fibrotic liver may exert a protective effect by inhibiting the translocation of HMGB1, a potent pro-inflammatory mediator.

MATERIALS AND METHODS

Animals and treatments

Male BALB/c mice (6-8-wk-old) were obtained from the Laboratory Animal Center, Academy of Military Medical Sciences, Beijing, China. The animal protocol was designed to minimize pain or discomfort in the mice. Mice were housed in a specific pathogen-free environment at 22-24 °C in a 12-h light-dark cycle. Animals were fed standard laboratory chow with free access to water. All animal care and experimental procedures performed in this study were in accordance with the guidelines for experimental animals approved by the Animal Care and Use Committee of Capital Medical University, China.

Mice were treated as follows: (1) induction of fibrosis: BALB/c mice received an intraperitoneal injection of carbon tetrachloride (CCl₄) in mineral oil, twice weekly, for 6 wk. The initial dose of CCl₄ was 0.2 µL/g (2%), and the dose was gradually increased up to 3 µL/g (30%); and (2) acute challenge: Control and fibrotic mice received intraperitoneal injection of a lethal dose of hepatic toxins (1 mg/g D-GalN + 50 ng/g LPS; Sigma-Aldrich, St Louis, MO, United States). Sera and liver tissues were harvested 24 h after acute injury for analysis. A portion of the liver was fixed in 10% neutral-buffered formalin for histological analysis and immunostaining. The remaining liver was cut into pieces and snap-frozen for homogenization to extract total liver RNA.

Evaluation of liver injury

Serum ALT levels were measured using a multi-parameteric analyzer (AU 5400; Olympus, Tokyo, Japan) according to an automated procedure. Formalin-fixed liver tissues were embedded in paraffin, sectioned and stained with hematoxylin-eosin for light microscopy.

Isolation of hepatic non-parenchymal cells and KCs

Hepatic non-parenchymal cells (NPCs) were isolated from mice by collagenase digestion and differential centrifugation using a previously reported method with some modifications^[22]. Briefly, *in situ* perfusion was applied through the portal vein and superior vena cava with 0.9% NaCl followed by DMEM/F12 (Gibco, Grand Island, NY, United States) containing 0.5% Pronase (Roche Diagnostics GmbH, Mannheim, Germany) and DMEM/F12 containing 0.04% type IV collagenase (Sigma-Aldrich). The liver was then harvested, excised

and digested with DMEM/F12 containing 10 µg/mL DNase (Sigma-Aldrich). Digested livers were passed through a 70 µm cell strainer (BD Falcon, Franklin Lakes, NJ, United States). The filtrate was centrifuged and washed. The pellets were re-suspended in DMEM (Hyclone, Logan, UT, United States), and then overlaid onto a Percoll (Amersham Pharmacia Biotechnology, Buckinghamshire, United Kingdom) gradient (40%-70%), and centrifuged at 1100 × *g* for 20 min. NPCs were collected from the interface for further purification.

To purify KCs, the liver NPC suspension was further overlaid onto the Percoll gradient (25%-50%), and centrifuged at 1800 × *g* for 30 min. The KC-enriched NPCs in the interface were harvested and washed. The isolated KCs were then cultured in DMEM medium containing 10% fetal bovine serum (Hyclone) and 1% penicillin-streptomycin (Sigma-Aldrich) in a humidified chamber at 37 °C with 5% CO₂. Following incubation for 2 h, the unattached cells were gently removed. The remaining adhered cells were further cultured for 24 h, and the phenotype of KCs was characterized by real-time PCR.

Reverse transcription and SYBR Green real-time quantitative PCR

Total RNA was extracted from isolated KCs using TRIzol reagent (Invitrogen, Carlsbad, CA, United States) following the manufacturer's instructions. Reverse transcription of the purified RNA (2.5 µg) was performed using random primers and the AMV retrotranscriptase system (TakaRa, Dalian, Liaoning, China) according to the manufacturer's protocol. SYBR Green real-time PCR was carried out using the ABI StepOne Plus (Applied Biosystems, Foster City, CA, United States). All reactions were performed in triplicate. In a final reaction volume of 20 µL, the followings were added: 1× SYBR Green (TakaRa), cDNA, 0.5 mmol/L of each primer, and ROX. The reaction conditions were as follows: 50 °C (2 min), 95 °C (5 min), followed by 40 cycles at 95 °C (15 s) and 60 °C (30 s). The primers used were designed with Primer 3.0 software and are listed in Table 1. The relative expression of target genes was calculated and normalized to the expression of the housekeeping gene GAPDH.

Treatment of isolated KCs with LPS or HMGB1 peptide

KCs isolated from control and fibrotic mice were cultured in DMEM medium for 24 h. The KCs were then treated with LPS (10 ng/mL) or HMGB1 peptide (FKDPNAPKRLPSAFLFCSE) (30 µg/mL; SBS Genetech Co, Ltd, Beijing, China) for another 20 h. Translocation of HMGB1 in KCs was analyzed by immunofluorescence staining.

Immunofluorescence staining

Frozen liver sections (or KCs) were fixed with 4%

Table 1 Primer sequences used for reverse transcription-quantitative polymerase chain reaction analysis

Genes	Sense (5'-3')	Anti-sense (5'-3')
GAPDH	AACCTTGGCATTGTGGAAGG	ACACATIGGGGGTAGGAACA
IL-1 β	GCCCATCCTCTGTGACTCAT	AGGCCACAGGTATTTTGT
TNF- α	GCCCTCTCTCATTCCTGCTTG	TGAGATCCATGCCGTTG
CD206	ATGCCAAGTGGGAAAATCTG	TGTAGCAGTGGCCTGCATAG
iNOS	CGGAGCCTTTAGACCTCAACA	CCCTCGAAGGTGAGCTGAAC
YM-1	ATCTATGCCTTGTGCTGGAATGC	TGAATGAATATCTGACGGTTCTGAG
CCL17	TGCTTCTGGGGACTTTTCTG	TGGCCTTCTTCACATGTTTG

paraformaldehyde for 30 min at room temperature. Slices (or KCs) were treated with 0.2% Triton X-100 for 5 min. The slices (or KCs) were then incubated with Tris-buffered saline (TBS) containing 5% fetal bovine serum for 30 min. Immunofluorescence staining was performed using the following primary antibodies: rat anti-mouse F4/80 antigen Alexa Fluor® 488 (clone BM8; eBioscience, San Diego, CA, United States), rabbit anti-mouse HMGB1 (Epitomics, Burlingame, CA, United States), and goat anti-mouse type I collagen (Col-1) (SouthernBiotech, Birmingham, AL, United States). For indirect immunofluorescence staining, FITC-conjugated (Santa Cruz Biotechnology, Inc, Dallas, TX, United States) or Cy3-conjugated anti-rabbit IgG (Sigma-Aldrich) for HMGB1, and Cy3-conjugated rabbit anti-goat IgG for Col-1 (Sigma-Aldrich) were used. A Nikon inverted fluorescence microscope ECLIPSE Ti and NIS-Elements F3.0 software (Nikon Corporation, Tokyo, Japan) were used for image capture.

HMGB1 immunohistochemical staining

After deparaffinization and rehydration, the embedded liver sections were treated with 3% H₂O₂ for 15 min, followed by microwave antigen retrieval for a further 15 min in citrate buffer. The nonspecific proteins were blocked with 10% goat serum for 30 min. For HMGB1 staining, the specimens were incubated with a rabbit anti-mouse HMGB1 monoclonal antibody (Abcam, Cambridge, MA, United States) overnight at 4 °C, followed by 30 min incubation with horseradish-peroxidase-conjugated goat anti-rabbit secondary antibody (Zhongshan Golden Bridge Biotechnology Co., Ltd., Beijing, China). The sections were incubated with diaminobenzidine as a chromogenic substrate and counterstained with hematoxylin, dehydrated, and stabilized with mounting medium. Images were captured using an Olympus Bx51 microscope (Olympus America, Melville, NY, United States) and CellSens standard 1.4.1 software.

Animal care and use statement

All animal care and experimental procedures performed in this study were in accordance with the guidelines for experimental animals approved by the Animal Care and Use Committee of Capital Medical University, China.

Statistical analysis

Results were expressed as mean \pm SE of the values obtained. Group comparisons were performed using one-way analysis of variance (ANOVA) followed by Newman-Keuls multiple comparison test. Statistics and graphs were generated using Prism 5.0 software (GraphPad Software Inc, San Diego, CA, United States). $P < 0.05$ was considered statistically significant. The statistical methods used in this study were reviewed by Dr. Jun-Feng Li from the First Affiliated Hospital of Lanzhou University, Lanzhou, China.

RESULTS

Inhibition of HMGB1 expression is accompanied by injury resistance in the setting of liver fibrosis

We first assessed hepatic injury in control and fibrotic mice with or without acute insult. As shown in Figure 1, the D-GalN/LPS challenge triggered a sharp increase in serum ALT levels in control mice, which corresponded well with the pathological findings. In contrast, fibrotic mice showed marked resistance to the same insult. In particular, hepatic damage was significantly alleviated in fibrotic mice following the D-GalN/LPS challenge compared with control mice treated in the same way, as shown by improved hepatic histology and reduced serum ALT levels (Figure 1A and B). HMGB1, a potent and classic pro-inflammatory mediator, was induced in acutely injured mice. However, the expression of HMGB1 was markedly inhibited in fibrotic mice, even under acute challenge (Figure 1C). These findings suggest that liver fibrosis protects mice against acute insult, which is accompanied by inhibition of HMGB1 expression.

Kupffer cells may be involved in HMGB1-related injury resistance in the setting of liver fibrosis

Kupffer cells are involved in the progression and resolution of liver fibrosis. Recently, KCs have been documented to possess protective effects against hepatocyte apoptosis. In light of this finding, we hypothesized that KCs are involved in HMGB1-related injury resistance in the setting of liver fibrosis. To explore this hypothesis, we analyzed the expression and distribution of KCs and HMGB1 in fibrotic liver




Figure 1 Inhibition of High mobility group box 1 expression is closely associated with the injury resistance in the setting of liver fibrosis. Control and fibrotic mice (treated with CCl₄ for 6 wk) were challenged with a lethal dose of D-GalN (1 mg/g)/LPS (50 ng/g), and hepatic damage was assessed by histology (A: HE staining; original magnification, $\times 200$) and serum ALT levels (B). ^a $P < 0.05$ vs the control group, ^b $P < 0.05$ vs the fibrosis group, ^c $P < 0.05$ vs the fibrosis + D-GalN/LPS group. The expression of HMGB1 was determined by immunohistochemical staining (C: original magnification, $\times 200$). Data are expressed as mean \pm SEM. CCl₄: Carbon tetrachloride; D-GalN: D-galactosamine; HMGB1: High mobility group box 1; LPS: Lipopolysaccharide.




Figure 2 Kupffer cells may be involved in High mobility group box 1-mediated injury resistance. The expression and localization of F4/80 (a surrogate marker of KCs), HMGB1, and Col-1 were determined by immunofluorescence staining (original magnification, $\times 100$). Col-1: Type I collagen; HMGB1: High mobility group box 1; KCs: Kupffer cells.

by immunofluorescent staining. F4/80, a surrogate marker of KCs, was found to be co-localized with Col-1, supporting the key function of KCs in the pathogenesis of hepatic fibrosis (Figure 2). Interestingly, the co-localization of F4/80, HMGB1 and Col-1 was also found in fibrotic liver (Figure 2), which indicated functional interactions among KCs, the injury mediator HMGB1, and hepatic fibrosis. Thus, KCs may be involved in HMGB1-related injury resistance in the setting of

hepatic fibrosis.

Kupffer cells in fibrotic liver exhibit a predominant M2-like activation

We next sought to answer the question of how do KCs function in HMGB1-related injury resistance in the setting of liver fibrosis? It has been well established that macrophages are heterogeneous, and their functional plasticity is driven by microenvironmental




Figure 3 Kupffer cells in the fibrotic liver exhibit predominantly a M2-like activation. KCs were isolated from the livers of normal, acutely injured (D-GalN/LPS) and fibrotic mice, and M1 and M2 gene signatures were then determined by quantitative real-time PCR. Data are expressed as mean \pm SEM. ^a $P < 0.05$ vs the control group, ^b $P < 0.05$ vs the D-GalN/LPS group, ^c $P < 0.05$ vs the control group, ^d $P < 0.05$ vs the fibrosis group. D-GalN: D-galactosamine; KCs: Kupffer cells; LPS: Lipopolysaccharide.

signals which shape their properties through a wide spectrum of phenotypes^[23,24]. Thus, we characterized the phenotype of KCs by their representative markers. KCs were isolated from the livers of normal, acutely injured and fibrotic mice, and M1 and M2 gene signatures were then determined by quantitative real-time PCR. Fibrosis triggered marked up-regulation of M2 markers, including CD206, CCL17 and YM-1. However, macrophages from the acutely injured liver showed no increase or a moderate increase in these M2 signatures (Figure 3). On the other hand, iNOS, a marker of M1 activation, was substantially induced in KCs isolated from the acutely injured liver, but remained unchanged in KCs from the fibrotic liver (Figure 3). Therefore, KCs in fibrotic mice exhibit a predominantly M2-like phenotype.

Translocation of HMGB1 is inhibited in M2-like KCs following LPS or HMGB1 peptide stimuli

How do M2-like KCs and HMGB1 orchestrate injury resistance in the setting of hepatic fibrosis? We speculated that M2-like KCs in fibrotic liver may prevent the translocation of HMGB1 upon acute challenge, thereby hampering its critical function as a DAMP. To confirm our speculation, the translocation of HMGB1 was analyzed in KCs isolated from control and fibrotic mice and treated with LPS or HMGB1 peptide. Both LPS and HMGB1 peptide elicited the translocation of intranuclear HMGB1 in KCs isolated from control mice (Figure 4). Interestingly, HMGB1 was localized in the nucleus of the majority of M2-like KCs isolated

from fibrotic liver. Importantly, neither LPS nor HMGB1 peptide elicited the translocation of HMGB1 in M2-like KCs (Figure 4). Collectively, our *in vitro* data demonstrated that the translocation of HMGB1 was inhibited in M2-like KCs upon acute insult.

DISCUSSION

In the present study, we found that liver fibrosis protects mice against D-GalN/LPS challenge, and M2-like KCs in fibrotic liver may exert a protective effect by inhibiting the translocation of HMGB1, a crucial pro-inflammatory mediator. Our findings may provide a potential explanation for the mechanism of injury resistance in the setting of liver fibrosis.

The deleterious effects resulting from liver fibrosis, including cirrhosis, liver failure and hepatocellular carcinoma, are widely accepted. Recent studies have reported the hepatoprotective effects conferred by liver fibrosis. In a mouse model of partial bile duct ligation (PBDL), injured ligated lobes exhibited improved tolerance to TNF- α - and Fas-induced hepatocyte apoptosis, compared with non-ligated lobes^[10]. Similarly, thioacetamide-induced fibrotic liver was less vulnerable to acute injury^[8]. In the present study, we found that CCl₄-induced liver fibrosis conferred significant protection against a lethal challenge with D-GalN/LPS, as shown by improved hepatic histology and reduced serum ALT levels. Importantly, we linked HMGB1 with injury resistance in the setting of liver fibrosis. HMGB1 is an evolutionarily conserved non-




Figure 4 Translocation of High mobility group box 1 triggered by lipopolysaccharide or High mobility group box 1 peptide is inhibited in M2-like Kupffer cells. KCs were isolated from the livers of control and fibrotic mice, and then treated with LPS (10 ng/mL) or HMGB1 peptide (30 μ g/mL). The translocation of HMGB1 in KCs was analyzed by immunofluorescence staining (original magnification, $\times 200$). HMGB1: High mobility group box 1; KCs: Kupffer cells; LPS: Lipopolysaccharide.

histone nuclear protein with abundant expression in most mammalian cells. Recently, HMGB1 was identified as a potent pro-inflammatory mediator. Compared with ALT levels, HMGB1 is more sensitive at identifying acetaminophen-induced acute liver injury^[20,21]. In our study, in comparison with acutely injured liver, the expression of HMGB1 was markedly inhibited in fibrotic liver following acute challenge, which corresponded well with a significant improvement in liver histology. These findings provide powerful evidence for injury resistance conferred by liver fibrosis.

Hepatoprotection in the setting of liver fibrosis is an interesting subject and remains to be fully elucidated. Bourbonnais *et al.*^[8] attributed a hepatoprotective response to Col-1 produced during liver fibrosis, which significantly protected hepatocytes against toxic stimuli *via* activation of ERK1 signaling. The study by Osawa *et al.*^[9] specifically addressed the role of KCs in cholestatic liver injury using PBDL mice. They found that KCs reduced liver damage, and induced hepatocyte survival and regeneration. These protective and regenerative effects require activation of AKT in hepatocytes and SphK in HSCs^[9]. In the present study, KCs were co-localized with HMGB1 in fibrotic liver, indicating the critical role of KCs in HMGB1-related injury resistance in the setting of hepatic fibrosis.

We then explored the hepatoprotective effect of KCs in fibrotic mice from a new perspective, *i.e.*, the activation phenotype of KCs. Our hypothesis was based on the strong association between the function and phenotype of macrophages, as mentioned in the

introduction. According to our data, KCs exhibited a predominantly M2-like phenotype in the context of liver fibrosis, which is in line with the latest report on congenital hepatic fibrosis^[25]. Finally, we examined the underlying mechanism concerning the potential protective effect of M2-like KCs on HMGB1-related injury resistance in the setting of hepatic fibrosis. As previously noted, nuclear-cytoplasmic translocation is regarded as a key step in HMGB1 functioning as a DAMP, which in turn, triggers inflammation. Accordingly, we speculated that M2-like KCs may inhibit the translocation of HMGB1 induced by acute insult. Hence, we compared HMGB1 translocation in KCs isolated from control and fibrotic mice challenged with LPS or HMGB1 peptide. Both LPS and HMGB1 peptide triggered the translocation of intranuclear HMGB1 in KCs from control mice. However, the translocation of HMGB1 was markedly inhibited in M2-like KCs, even under acute challenge. These results provide strong support for our hypothesis, that is, M2-like KCs in fibrotic liver may protect against acute insult by inhibiting the translocation of HMGB1, thereby suppressing HMGB1-mediated pro-inflammatory responses and attenuating hepatic injury^[26].

Post-translational modification seems to be a critical step in regulation of the translocation and secretion of HMGB1 during inflammatory responses. The acetylation of HMGB1 on lysine residues in response to IL-1 β , TNF- α , and LPS is regarded as the most feasible and effective way^[27]. A recent study has shown that ligand-activated peroxisome proliferator-

activated receptor (PPAR)- δ and PPAR- γ modulate LPS-primed release of HMGB1 through SIRT-mediated deacetylation, which in turn, plays a critical role in the cellular response to inflammation^[28]. Whether this modulation occurred in our model requires further investigation. Moreover, we cannot exclude the passive release of HMGB1 by injured hepatocytes, as reported by Kao *et al.*^[29]. However, active secretion of HMGB1 by macrophages is also important in the context of fibrosis.

In conclusion, although the current findings are preliminary and may be speculative, our findings may shed new light on the pathogenesis of acute hepatic damage in the setting of liver fibrosis. We will elaborate the mechanisms underlying injury resistance by modulating the polarization and function of hepatic macrophages or by blocking HMGB1 signaling. From a clinical perspective, our study findings may pave the way for the treatment of liver failure, particularly acute-on-chronic liver failure.

COMMENTS

Background

Convincing evidence has shown that fibrosis confers increased liver resistance to subsequent acute insults, thus protecting hepatocytes against various toxic stimuli. The hepatoprotection conferred by liver fibrosis is intriguing and the mechanism of such protection remains to be fully elucidated.

Research frontiers

Kupffer cells (KCs) have been reported to exert a protective effect against hepatocyte apoptosis in cholestatic liver disease, indicating the potential role of KCs in hepatoprotection. Nevertheless, whether and how the phenotype of KCs is involved in injury resistance in the setting of liver fibrosis is poorly understood.

Innovations and breakthroughs

This study showed that liver fibrosis protects mice against D-GalN/lipopolysaccharide (LPS) challenge, and M2-like KCs in fibrotic liver may exert a protective effect by inhibiting the translocation of HMGB1.

Applications

The findings from this study may provide a potential explanation for the mechanism of injury resistance in the setting of liver fibrosis. From a clinical perspective, these findings may pave the way for the treatment of liver failure, particularly acute-on-chronic liver failure.

Terminology

Macrophages can undergo "classical" M1 activation when exposed to LPS and interferon- γ or "alternative" M2 activation when exposed to interleukin (IL)-4/IL-13. M1- and M2-like macrophages exhibit distinct signatures and fulfill different functions. HMGB1 has diverse functions which depend on its cellular localization. In the intracellular compartment, HMGB1 participates in gene transcription, DNA replication, and DNA repair. To function in a damage-associated molecular pattern, HMGB1 can translocate from the nucleus to the cytoplasm and is subsequently released into the extracellular milieu. Extracellular HMGB1 activates pro-inflammatory signaling pathways by ligation of pattern recognition receptors, leading to severe damage in multiple liver diseases.

Peer-review

This study is well designed, and the results are very interesting. In this study, the authors investigated the mechanism of hepatoprotection conferred by

liver fibrosis, evaluated the phenotype of KCs isolated from fibrotic liver. KCs isolated from the fibrotic mice exhibited predominantly an M2-like phenotype. *In vitro* experiments have shown that HMGB1 was localized in the nucleus of the majority of M2-like KCs and the translocation of HMGB1 was inhibited upon LPS or HMGB1 peptide stimuli, while both LPS and HMGB1 peptide could elicit the conspicuous translocation of intranuclear HMGB1 in KCs isolated from control mice.

REFERENCES

- Friedman SL. Liver fibrosis -- from bench to bedside. *J Hepatol* 2003; **38** Suppl 1: S38-S53 [PMID: 12591185]
- Battaller R, Brenner DA. Liver fibrosis. *J Clin Invest* 2005; **115**: 209-218 [PMID: 15690074 DOI: 10.1172/JCI24282]
- Ramachandran P, Iredale JP. Macrophages: central regulators of hepatic fibrogenesis and fibrosis resolution. *J Hepatol* 2012; **56**: 1417-1419 [PMID: 22314426 DOI: 10.1016/j.jhep.2011.10.026]
- Friedman SL. Mechanisms of hepatic fibrogenesis. *Gastroenterology* 2008; **134**: 1655-1669 [PMID: 18471545 DOI: 10.1053/j.gastro.2008.03.003]
- Friedman SL. Evolving challenges in hepatic fibrosis. *Nat Rev Gastroenterol Hepatol* 2010; **7**: 425-436 [PMID: 20585339 DOI: 10.1038/nrgastro.2010.97]
- White ES, Mantovani AR. Inflammation, wound repair, and fibrosis: reassessing the spectrum of tissue injury and resolution. *J Pathol* 2013; **229**: 141-144 [PMID: 23097196 DOI: 10.1002/path.4126]
- Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. *Nat Med* 2012; **18**: 1028-1040 [PMID: 22772564 DOI: 10.1038/nm.2807]
- Bourbonnais E, Raymond VA, Ethier C, Nguyen BN, El-Leil MS, Meloche S, Bilodeau M. Liver fibrosis protects mice from acute hepatocellular injury. *Gastroenterology* 2012; **142**: 130-139.e4 [PMID: 21945831 DOI: 10.1053/j.gastro.2011.09.033]
- Osawa Y, Seki E, Adachi M, Suetsugu A, Ito H, Moriawaki H, Seishima M, Nagaki M. Role of acid sphingomyelinase of Kupffer cells in cholestatic liver injury in mice. *Hepatology* 2010; **51**: 237-245 [PMID: 19821528 DOI: 10.1002/hep.23262]
- Osawa Y, Hannun YA, Proia RL, Brenner DA. Roles of AKT and sphingosine kinase in the antiapoptotic effects of bile duct ligation in mouse liver. *Hepatology* 2005; **42**: 1320-1328 [PMID: 16317686 DOI: 10.1002/hep.20967]
- Ju C, Tacke F. Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies. *Cell Mol Immunol* 2016; **13**: 316-327 [PMID: 26908374 DOI: 10.1038/cmi.2015.104]
- Possamai LA, Thursz MR, Wendon JA, Antoniadou CG. Modulation of monocyte/macrophage function: a therapeutic strategy in the treatment of acute liver failure. *J Hepatol* 2014; **61**: 439-445 [PMID: 24703954 DOI: 10.1016/j.jhep.2014.03.031]
- Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. *Nat Immunol* 2010; **11**: 889-896 [PMID: 20856220 DOI: 10.1038/ni.1937]
- Sica A, Invernizzi P, Mantovani A. Macrophage plasticity and polarization in liver homeostasis and pathology. *Hepatology* 2014; **59**: 2034-2042 [PMID: 24115204 DOI: 10.1002/hep.26754]
- Tacke F, Zimmermann HW. Macrophage heterogeneity in liver injury and fibrosis. *J Hepatol* 2014; **60**: 1090-1096 [PMID: 24412603 DOI: 10.1016/j.jhep.2013.12.025]
- Wynn TA, Barron L. Macrophages: master regulators of inflammation and fibrosis. *Semin Liver Dis* 2010; **30**: 245-257 [PMID: 20665377 DOI: 10.1055/s-0030-1255354]
- Lotze MT, Tracey KJ. High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal. *Nat Rev Immunol* 2005; **5**: 331-342 [PMID: 15803152 DOI: 10.1038/nri1594]
- Dragomir AC, Laskin JD, Laskin DL. Macrophage activation by factors released from acetaminophen-injured hepatocytes: potential role of HMGB1. *Toxicol Appl Pharmacol* 2011; **253**: 170-177 [PMID: 21513726 DOI: 10.1016/j.taap.2011.04.003]

- 19 **Tang D**, Kang R, Van Houten B, Zeh HJ, Billiar TR, Lotze MT. High mobility group box 1 (HMGB1) phenotypic role revealed with stress. *Mol Med* 2014; **20**: 359-362 [PMID: 24937773 DOI: 10.2119/molmed.2014.00063]
- 20 **Antoine DJ**, Jenkins RE, Dear JW, Williams DP, McGill MR, Sharpe MR, Craig DG, Simpson KJ, Jaeschke H, Park BK. Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. *J Hepatol* 2012; **56**: 1070-1079 [PMID: 22266604 DOI: 10.1016/j.jhep.2011.12.019]
- 21 **Antoine DJ**, Dear JW, Lewis PS, Platt V, Coyle J, Masson M, Thanacoody RH, Gray AJ, Webb DJ, Moggs JG, Bateman DN, Goldring CE, Park BK. Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital. *Hepatology* 2013; **58**: 777-787 [PMID: 23390034 DOI: 10.1002/hep.26294]
- 22 **Jung K**, Kang M, Park C, Hyun Choi Y, Jeon Y, Park SH, Seo SK, Jin D, Choi I. Protective role of V-set and immunoglobulin domain-containing 4 expressed on kupffer cells during immune-mediated liver injury by inducing tolerance of liver T- and natural killer T-cells. *Hepatology* 2012; **56**: 1838-1848 [PMID: 22711680 DOI: 10.1002/hep.25906]
- 23 **Wan J**, Benkdane M, Teixeira-Clerc F, Bonnafous S, Louvet A, Lafdil F, Pecker F, Tran A, Gual P, Mallat A, Lotersztajn S, Pavoine C. M2 Kupffer cells promote M1 Kupffer cell apoptosis: a protective mechanism against alcoholic and nonalcoholic fatty liver disease. *Hepatology* 2014; **59**: 130-142 [PMID: 23832548 DOI: 10.1002/hep.26607]
- 24 **Murray PJ**, Wynn TA. Protective and pathogenic functions of macrophage subsets. *Nat Rev Immunol* 2011; **11**: 723-737 [PMID: 21997792 DOI: 10.1038/nri3073]
- 25 **Locatelli L**, Cadamuro M, Spirli C, Fiorotto R, Lecchi S, Morell CM, Popov Y, Scirpo R, De Matteis M, Amenduni M, Pietrobattista A, Torre G, Schuppan D, Fabris L, Strazzabosco M. Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis. *Hepatology* 2016; **63**: 965-982 [PMID: 26645994 DOI: 10.1002/hep.28382]
- 26 **Kono H**, Onda A, Yanagida T. Molecular determinants of sterile inflammation. *Curr Opin Immunol* 2014; **26**: 147-156 [PMID: 24556412 DOI: 10.1016/j.coi.2013.12.004]
- 27 **Bonaldi T**, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A, Rubartelli A, Agresti A, Bianchi ME. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. *EMBO J* 2003; **22**: 5551-5560 [PMID: 14532127 DOI: 10.1093/emboj/cdg516]
- 28 **Hwang JS**, Lee WJ, Kang ES, Ham SA, Yoo T, Paek KS, Lim DS, Do JT, Seo HG. Ligand-activated peroxisome proliferator-activated receptor- δ and - γ inhibit lipopolysaccharide-primed release of high mobility group box 1 through upregulation of SIRT1. *Cell Death Dis* 2014; **5**: e1432 [PMID: 25275593 DOI: 10.1038/cddis.2014.406]
- 29 **Kao YH**, Lin YC, Tsai MS, Sun CK, Yuan SS, Chang CY, Jawan B, Lee PH. Involvement of the nuclear high mobility group B1 peptides released from injured hepatocytes in murine hepatic fibrogenesis. *Biochim Biophys Acta* 2014; **1842**: 1720-1732 [PMID: 24970745 DOI: 10.1016/j.bbdis.2014.06.017]

P- Reviewer: Chadokufa S, Hatta W **S- Editor:** Gong ZM
L- Editor: Filipodia **E- Editor:** Zhang FF





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgooffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>



ISSN 1007-9327

